EDP Sciences logo
Submit your paper
Search
Menu
All issues Volume 44 / No 3 (September 2012) J Extra Corpor Technol, 44 3 (2012) 145-150 References
Free Access
Issue
J Extra Corpor Technol
Volume 44, Number 3, September 2012
Page(s) 145 - 150
DOI https://doi.org/10.1051/ject/201244145
Published online 15 September 2012
  1. Ïvrum E, Mollnes TE, Fosse E, et al. High and low heparin dose with heparin-coated cardiopulmonary bypass: Activation of complement and granulocytes. Ann Thorac Surg. 1995;60:1755–1761. [CrossRef] [Google Scholar]
  2. Metz S, Keats AS. Low activated coagulation time during cardiopulmonary bypass does not increase postoperative bleeding. Ann Thorac Surg. 1990;49:440–444. [CrossRef] [Google Scholar]
  3. Gravlee GP, Rogers AT, Dudas LM, et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology. 1992;76:393–401. [CrossRef] [PubMed] [Google Scholar]
  4. Despotis GJ, Joist JH. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: An update. J Cardiothorac Vasc Anesth. 1999;13:18–29. [CrossRef] [Google Scholar]
  5. Koster A, Fischer T, Praus M, et al. Hemostatic activation and inflammatory response during cardiopulmonary bypass: Impact of heparin management. Anesthesiology. 2002;97:837–841. [CrossRef] [PubMed] [Google Scholar]
  6. Koster A, Huebler S, Merkle F, et al. Heparin-level-based anticoagulation management during cardiopulmonary bypass: A pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response. Anesth Analg. 2004;98:285–290, table. [CrossRef] [PubMed] [Google Scholar]
  7. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood. 1990;76:1680–1697. [CrossRef] [PubMed] [Google Scholar]
  8. Bull BS, Huse WM, Brauer FS, Korpman RA. Heparin therapy during extracorporeal circulation. II. The use of a dose–response curve to individualize heparin and protamine dosage. J Thorac Cardiovasc Surg. 1975;69:685–689. [CrossRef] [Google Scholar]
  9. Bull BS, Korpman RA, Huse WM, Briggs BD. Heparin therapy during extracorporeal circulation. I. Problems inherent in existing heparin protocols. J Thorac Cardiovasc Surg. 1975;69:674–684. [CrossRef] [Google Scholar]
  10. Teoh KH, Young E, Blackall MH, Roberts RS, Hirsh J. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg. 2004;128:211–219. [CrossRef] [Google Scholar]
  11. Chatterjee S, Hadi AS. Regression Analysis by Example. 2006 4th. Hoboken, NJ: Wiley-Interscience. [CrossRef] [Google Scholar]
  12. Gravlee GP, Davis RF, Stammers AH, Ungerleider RM. Cardiopulmonary Bypass: Principles and Practice. 2007 3rd Ed. Philadelphia, PA: Lippincott Williams and Wilkins. [Google Scholar]
  13. Alderman EL, Levy JH, Rich JB, et al. Analyses of coronary graft patency after aprotinin use: Results from the InternationalMulticenter Aprotinin Graft Patency Experience (IMAGE) trial. J Thorac Cardiovasc Surg. 1998;116:716–730. [CrossRef] [Google Scholar]
  14. Despotis GJ, Joist JH, Hogue CWJr, et al. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation. J Thorac Cardiovasc Surg. 1995;110:46–54. [CrossRef] [Google Scholar]
  15. Raivio P, Kuitunen A, Petäjä J, Ilveskero S, Lassila R. Monitoring high-dose heparinization during cardiopulmonary by-pass—A comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays. Thromb Haemost. 2008;99:427–434. [CrossRef] [PubMed] [Google Scholar]
  16. Bosch YP, Ganushchak YM, de Jong DS. Comparison of ACT point-of-care measurements: Repeatability and agreement. Perfusion. 2006;21:27–31. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.